We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New Approach Improves Identification of Women at High Risk of Preeclampsia

By LabMedica International staff writers
Posted on 05 May 2016
Print article
A new meta-analysis examining 92 cohort studies involving over 25 million pregnancies has provided an unprecedented understanding of risk factors for preeclampsia—some risk factors being strong enough to warrant that a pregnant woman starts on prophylactic treatment with acetylsalicylic acid (ASA) when she has only one.

Researchers led by Dr. Joel Ray of St. Michael’s Hospital (Toronto, Ontario, Canada) have developed a new tool that can improve how clinicians identify women at high risk of developing preeclampsia, and who should take ASA (i.e., aspirin). Clinical practice guidelines recommend that women at high risk take ASA daily at low-dose (“baby aspirin”) starting at 12–20 weeks of pregnancy.

The new meta-analysis identified several risk factors that alone, or in combination, provide a clear, concise, evidence-based approach to identifying these women based on routinely collected clinical information. Also importantly, even though ASA is safe in pregnancy, the tool helps distinguish women who are unlikely to benefit from ASA therapy.

Preeclampsia affects approximately 3% of women, and is characterized by onset of elevated blood pressure in later pregnancy. It can cause a woman to seize or have a stroke or kidney failure, and can put fetuses at risk of premature birth and poor growth.

The new study started with the idea that a woman at a 7%–10% or higher chance of developing preeclampsia is a candidate for preventive therapy with ASA. The researchers examined large cohort studies (over 1,000 women each) and pooled the results to determine which individual risk factors pass that threshold.

Some risk factors identified are strong enough that a woman should likely be started on ASA when she has only one factor. These include having had preeclampsia in a previous pregnancy, or diabetes or chronic hypertension prior to the current pregnancy. For example, having chronic hypertension alone produces an absolute risk of 16% of developing preelampsia, compared to a risk of 3% in the absence of chronic hypertension or other risk factors.

However, some risk factors are not strong enough on their own, so a woman would need to have 2 or3 to warrant ASA treatment. For example, a woman who has chronic kidney disease has about a 6% of developing preeclampsia, probably not high enough alone. Among the list requiring 2 or more risk factors are a prior stillbirth or separation of the placenta from the uterus wall, or in the current pregnancy: recognized chronic kidney disease, twins or triplets, lupus, first-time pregnancy, or age > 40 years.

"We can now identify the most influential clinical factors for preeclampsia, none of which require special testing, and all are currently collected by a midwife, obstetrician, family doctor, or nurse practitioner at a woman's routine pregnancy visit," said Dr. Ray, "While ASA may reduce the risk of pre-eclampsia, we really want to ensure that only a woman truly at high risk goes on ASA, while making it very easy for any clinician to identify that person."

The study was published April 19, 2016, in the journal BMJ.

Related Links:
St. Michael’s Hospital

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
New
Rapid Test Analyzer
RapiRead CUBE Reader
New
Silver Supplier
HSV1+2 / VZV Test
Savvygen HSV1+2 / VZV

Print article

Channels

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.